
FIG. 1



	KMS11	OPM2	H929
BOTTOM (Constant)	0.0	0.0	0.0
TOP	1.5180e+006	1.3600e+006	1.5220e+006
LOGEC50	-7.225	-7.063	-5.583
HILLSLOPE	-0.8926	-0.9733	-1.890
EC50	5.9570e-008	8.6500e-008	2.6150e-006

FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4



Annexin(-) 7-AAD(-) Non-Apoptotic
Annexin(-) 7-AAD(+) Incompletely stained cells, free nuclei, cell debris
Annexin(+) 7-AAD(+) Late Stage Apoptotic, Necrotic, Dead
Annexin(+) 7-AAD(-) Early Stage Apoptotic
% of cells
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
DMSO (0.1%)
0.01uM
0.1uM
0.5uM
1.0uM
90.8%
4.6%
4.6%
90.0%
6.0%
4.0%
43.9%
45.2%
10.9%
12.2%
77.2%
10.6%
4.9%
87.4%
7.7%

FIG. 5



G2/M
S
G1
sub G1/G0
% cells
100%
80%
60%
40%
20%
0%
DMSO
0.001 µM
0.01 µM
0.1 µM
1 µM
12
37
27
13
36
27
24
40
19
55
31
8
68
19
8

FIG. 6



Annexin(-) 7-AAD(-) Non-Apoptotic
Annexin(-) 7-AAD(+) Incompletely stained cells, free nuclei, cell debris
Annexin(+) 7-AAD(+) Late Stage Apoptotic, Necrotic, Dead
Annexin(+) 7-AAD(-) Early Stage Apoptotic
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
DMSO 0.1%
0.01uM
0.1uM
0.5uM
1.0uM
64%
3%
25%
8%
58%
1%
27%
14%
53%
2%
33%
13%
47%
2%
35%
17%
36%
2%
43%
19%

FIG. 7



G2/M
S
G1
sub G1/G0
100%
80%
60%
40%
20%
0%
% cells
DMSO
0.01 µM
0.1 µM
0.5 µM
1 µM
14
25
43
15
26
41
18
20
43
26
19
44
31
11
34

FIG. 8



G2/M
S
G1
sub G1/G0
% cells
100%
80%
60%
40%
20%
0%
DMSO
0.01 µM
0.1 µM
0.5 µM
1 µM
15
53
12
15
51
12
17
50
12
16
49
14
13
48
18

FIG. 9



MNFS-60
ALU
1200000
1000000
800000
600000
400000
200000
0
-12.5
-10.0
-7.5
-5.0
-2.5
0.0
Log[M]
BOTTOM (CONSTANT) 992.0
TOP (Constant) 924783
LOG EC50 -6.651
HILLSLOPE -1.561
EC50 2.2350e-007

FIG. 10



J804C
Y373C
K650E
384D
WT+FGF
F84L+FGF
MIN+IL6
Viability (% of control)
120
100
80
60
40
20
0
0
12.5
25
50
100
200
300
400
4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one (nM)

FIG. 11





% Annexin V
60
50
40
30
20
10
0
KMS11
KMS18
OPM2
H929
8226
Human Myeloma Cell Lines

FIG. 12A



FGFR3

FIG. 12B



p-ERK1/2

FIG. 12C




FIG. 12D




FIG. 13A




FIG. 13B



Viability (% of control)
120
100
80
60
40
20
0
stroma
KMS11+stroma
KMS11

FIG. 14




% inhibition
100
80
60
40
20
0
-20
0.001
0.01
0.1
1
10
μM 4-Amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]quinolin-2(1H)-one

FIG. 15


Tumor Volume (mm3)
2000
1800
1600
1400
1200
1000
800
600
400
200
0
-7
-4
1
4
8
11
15
18
22
Days of Treatment
60mg/kg
30mg/kg
10mg/kg
Placebo